T1	intervention 10 19	letrozole
T2	control 27 34	placebo
T3	eligibility 68 143	with primary breast cancer completing 5 or more years of adjuvant tamoxifen
T4	location 317 323	Canada
T6	total-participants 970 992	Two hundred twenty-six
T7	intervention-participants 1003 1006	122
T8	control-participants 1018 1021	104
T9	age 1132 1142	60.7 years
T12	iv-cont-mean 1284 1289	-3.6%
T13	cv-cont-mean 1292 1298	-0.71%
T15	iv-cont-mean 1332 1338	-5.35%
T16	cv-cont-mean 1341 1347	-0.70%
T17	outcome 1380 1423	urine N-telopeptide at 6, 12, and 24 months
T19	iv-bin-percent 1649 1653	4.1%
T20	cv-bin-percent 1656 1658	0%
T5	outcome 1269 1282	total hip BMD
T10	outcome 1314 1330	lumbar spine BMD
T11	outcome 1524 1537	total hip BMD
T14	outcome 1602 1621	osteoporotic by BMD
